Bendamustine Hydrochloride and Corifact

• Generic Name: bendamustine
• Dosage Forms: n.a.
• Other Brand Names: Belrapzo, Bendeka, Treanda

Treatment of chronic lymphocytic leukemia (CLL) (designated an orphan drug by FDA for this use).

Prolonged progression-free survival and increased overall response rate observed with bendamustine compared with chlorambucil in patients with previously untreated, Binet stage B or C (Rai stages I–IV) CLL. Incidence of adverse effects generally also higher with bendamustine than with chlorambucil.

Efficacy of bendamustine relative to first-line therapies other than chlorambucil not established.

Treatment of rituximab-refractory, indolent, B-cell non-Hodgkin’s lymphoma (NHL).

Use in combination with rituximab for treatment of previously untreated advanced-stage indolent NHL or for treatment of previously untreated advanced-stage mantle cell lymphoma is a reasonable choice (accepted, with possible conditions); however, consider histologic subtype of NHL when selecting a combination chemotherapy regimen.

Use in combination with rituximab for treatment of relapsed or refractory indolent NHL or for treatment of relapsed or refractory mantle cell lymphoma is recommended (accepted).

• Generic Name: factor XIII
• Dosage Forms: injection
• Other Brand Names: Corifact, Tretten

Corifact (factor XIII) is used to prevent bleeding episodes in people with a hereditary bleeding disorder caused by a deficiency of Factor XIII.

Factor XIII (thirteen) is a naturally occurring protein in the blood that helps blood to clot. A lack of clotting factors can cause uncontrolled bleeding, as the blood is unable to clot properly. This medicine works by temporarily raising levels of these factor XIII in the blood to aid in clotting.

Corifact will not treat a bleeding episode that has already begun.

Corifact may also be used for purposes not listed in this medication guide.